Cargando…
Concept and design of a nationwide prospective feasibility/efficacy/safety study of weekly paclitaxel for patients with pathologically confirmed anaplastic thyroid cancer (ATCCJ-PTX-P2)
BACKGROUND: Anaplastic thyroid cancer (ATC) is one of the most aggressive malignancies in humans, often demonstrating resistance to multimodal therapeutic approaches. The median survival of ATC patients after initial diagnosis was reported to be < 6 months due to the rapid progression of disease...
Autores principales: | Onoda, Naoyoshi, Sugitani, Iwao, Higashiyama, Takuya, Hara, Hisato, Ito, Ken-ichi, Kammori, Makoto, Sugino, Kiminori, Suzuki, Shinichi, Toda, Kazuhisa, Yoshida, Akira, Miyauchi, Akira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4474467/ https://www.ncbi.nlm.nih.gov/pubmed/26091846 http://dx.doi.org/10.1186/s12885-015-1490-8 |
Ejemplares similares
-
Chemotherapy for anaplastic thyroid cancer using docetaxel and cisplatin: report of eight cases
por: Seto, Akira, et al.
Publicado: (2013) -
Evaluation of the 8th Edition TNM Classification for Anaplastic Thyroid Carcinoma
por: Onoda, Naoyoshi, et al.
Publicado: (2020) -
Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma
por: Ito, Yasuhiro, et al.
Publicado: (2017) -
Active Surveillance Versus Immediate Surgery: Questionnaire Survey on the Current Treatment Strategy for Adult Patients with Low-Risk Papillary Thyroid Microcarcinoma in Japan
por: Sugitani, Iwao, et al.
Publicado: (2019) -
Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma
por: Yamazaki, Haruhiko, et al.
Publicado: (2022)